Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EryDex Kinetics in Healthy Volunteers
NCT02380924Phase 1Completed
- Sponsor
- IRulya Therapeutics
- Start
- Jan 2015
- Primary completion
- Jun 2015
- Modality
- Nanoparticles, Small Molecules, Device-based Delivery
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of EryDex in ataxia-telangiectasia (AT) (2 arms), sponsored by IRulya Therapeutics. Primary endpoints: 24-hour post transfusion recovery of infused autologous RBCs and Long-term survival of infused autologous RBCs assessed with T50 up to 49 days. Started Jan 2015; status: completed.
02
Drugs
EryDex
03
Conditions
ataxia-telangiectasia (AT)
Beyond the preview
Go deeper on NCT02380924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02380924.